GOLDENWELL BIOTECH, INC. (GWLL) Form 10-K — Jun 30, 2026

Goldenwell Biotech, Inc. disclosed significant going concern risks in its fiscal year 2025 10-K, reporting minimal operations with total revenue of just $55 for the year. The company recorded a net loss of $296,471 and an accumulated deficit of $1,656,117, citing that its continuation is dependent on raising capital to fund its business plan. Management stated they need approximately $5,000,000 to construct manufacturing facilities and launch commercial sales of their licensed nutraceutical products.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.